Every project listed here is undergoing structured due diligence across technology, security, team, and regulatory alignment.
Preclinical biotechnology company focused on targeted gene and RNA therapies for rare genetic and neurodevelopmental disorders. Proprietary delivery platforms for brain, cartilage, and bone tissues.
View Launch ProfileDeveloping precision delivered RNA therapeutics for liver and brain. Lead program advancing toward IND enabling studies for liver disease, with a second program in neuro-oncology.
View Launch Profile
Scientific foundation, team track record, and regulatory feasibility are screened before any project is listed.
Integrated KYC/KYB, regional access controls, and alignment with securities regulations in relevant jurisdictions.
Seamless integration with RVA Wallet and Exchange for post-launch custody, trading, and governance.
The exact schedule depends on due diligence. A typical path for projects like Dawn and Apterna includes preparatory structuring, deep diligence, pre-launch disclosure, and finally the launch window.
Draft launch concept and initial data collection.
Deep checks on IP, team, and legal posture.
Investor materials, risk disclosures, and whitelist opening.
Sale scheduling only after all checks are complete.
Verify your RVA account and complete KYC/KYB to be ready.
Review scientific publications and RVA summaries carefully.
Professional investors can discuss allocations directly.
All projects shown are preclinical programmes. None of the therapies described are approved for use in humans. Any future tokens or digital instruments will be high risk, illiquid, and suitable only for investors who can afford to lose their capital.
Inclusion on this page does not constitute an offer, solicitation, or recommendation. RVA reserves the right to modify, delay, or cancel any potential Launchpad event.
Follow progress as Dawn, Apterna, and future projects move through the funnel.
